AZN vs INCY
AstraZeneca PLC vs Incyte — AI-powered side-by-side comparison
AZN
AstraZeneca PLC
56
Watch
VS
| Metric | AZN | INCY |
|---|
| AI Score |
56
|
72
|
| Price |
$158.74
|
$121.08
|
| P/E Ratio |
23.81×
|
14.89×
|
| ROE |
21.1%
|
24.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
79.3%
|
92.6%
|
| Debt / Equity |
0.64×
|
0.01×
|
| Dividend Yield |
1.3%
|
0.0%
|
| RSI (14) |
33.8
|
56.2
|
| Beta |
0.211
|
0.769
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for AZN versus INCY.
INCY leads by 16 points.
INCY scores 72/100 (Buy) versus AZN at 56/100 (Watch).
AZN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — current ratio of 0.94 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 21.7% shows genuine earnings power backing the valuation — Value
- EPS growing 25.9% YoY — Growth
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 5.9x prices in significant intangible value — Value
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical